Anbalcabtagene autoleucel

安基奥仑赛

Report date: 2023/05/05 18:02:38

Base Information

Drug NameAnbalcabtagene autoleucel
Drug Alias NameCRC-01
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLupus Erythematosus, SystemicLupus Nephritis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCurocell Inc
China Registration ClassN/A

Develop Information

Active CompaniesCurocell Inc
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLupus Erythematosus, SystemicLupus Nephritis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A